The world's first oral HER2-targeted drug for lung cancer made its debut at the China International Import Expo.

At the 8th China International Import Expo held on the 6th, Boehringer Ingelheim held a celebration for the listing of Sanctur China, marking a new stage for the treatment of HER2-mutated non-small cell lung cancer in China with oral targeted therapy. Prior to this, there had been no breakthrough in TKI targeted therapy in the field of HER2 lung cancer treatment, and the listing of Sanctur brings new treatment options and hope for HER2 lung cancer patients. Sanctur is the world's first and only orally available HER2 tyrosine kinase inhibitor approved for non-small cell lung cancer, suitable for the treatment of unresectable locally advanced or metastatic non-small cell lung cancer in adults with HER2-activating mutations who have previously received at least one systemic therapy.